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Abstract.

ROLE OF MDM2 IN CELL GROWTH REGULATION.
Rebecca A. Frum, Bachelor of Science, North Carolina State University, Raleigh NC

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2006.
Director: Swati Palit Deb, Ph.D., Associate Professor, Biochemistry
MDM2 has been shown to induce GO-Gl/S phase arrest. To determine the cell cycle
step targeted by MDM2, flow cytometry was employed to detect induction of events
during the GI-S phase transition in MDM2-arrested cells. MDM2 overexpression does
not prevent expression of cyclin D, cyclin D-CDK mediated phosphorylation of Rb or
cyclin E in normal, immortal or tumor-derived cells. However, MDM2 down-regulates
cyclin A expression specifically in normal cells, which is associated with G I arrest. The
domain of MDM2 capable of this function is located within its N-terminal 58-109 amino
acids. To down-regulate cyclin A, MDM2 requires a functional p l61Brg 1 pathway, as
silencing of either of these proteins disables this function of MDM2. Bromodeoxyuridine
incorporation studies suggest that another inhibitory domain, ID2, inhibits DNA
replication, while an MDM2 deletion mutant containing the N-terminal 1-220 amino
acids including inhibitory domain ID1 does not effectively prevent BrdU incorporation in
an immortal cell line that is non-responsive to growth arrest by the cyclin A inhibitory

domain. This suggests that induction of MDM2 leads to GI arrest by at least two
independent mechanisms, and multiple genetic damages are necessary to overcome
MDM2-mediated growth arrest. To determine novel interacting partners of MDM2,
proteomic analysis of MDM2 overexpressed in tumor-derived H1299 cells was carried
out. This analysis revealed interaction of MDM2 with the translation elongation factor
efl-a, and was validated by immunoprecipitation and Western blotting and shown to
colocalize with MDM2 in the cytoplasm. To interact with efl-a, MDM2 was determined
to require two domains, one of which is located within amino acids 221-325 and another
within the N-terminal58 amino acids of MDM2.

H. Chapter 1. Introduction
MDM2 is potentially oncogenic: The human homologue of the murine double
minute-2 gene (MDM2) is frequently overexpressed in many human carcinomas, soft
tissue sarcomas and other cancers (1-17). Amplification of the mdm2 gene enhances
the tumorigenic potential of murine cells (18,22). Overexpression of mdm2 messenger
RNA from the amplified gene (5,11,19-20) and enhanced translation of mRNA have
been proposed as mechanisms of MDM2 overexpression (12,21,23). These findings
suggest that MDM2 has oncogenic properties. Targeted overexpression of MDM2 in
transgenic mice causes polyploidy. Overexpression of MDM2 in breast epithelial cells
inhibits normal development of the mammary gland. (24). Targeted overexpression
of MDM2 in the basal layer of the epidermis increases papilloma formation by
chemical carcinogens (25). These findings suggest the requirement of added genetic
damage for MDM2-induced tumorigenesis.

MDM2 interacts with the tumor suppressor p53: MDM2 recognizes the
transactivation domain of p53 and this interaction physically blocks p53-mediated
transcriptional activation (19,26-31). Work from our laboratory showed that the
interaction of MDM2 with p53 is needed for inhibition of p53-mediated transactivation
(27,29). Consistent with its ability to inhibit p53-mediated transactivation, MDM2
inhibits p53-mediated growth suppression and apoptosis in tumor-derived cells (32-34).
The p53-regulatory function of MDM2 is required for embryonic development (35,36).
Wild-type p53 induces MDM2 expression through the P2 promoter by recognizing
a response element situated downstream of the first exon of the oncogene (37-39).
Thus, presence of an autoregulatory feedback loop has been suggested, in which a
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splFigure 1. Domains of MDM2. Domains of MDM2 identified for various protein
interactions and other functions are shown.
higher level of p53 expression will arrest the cell cycle at the G1 phase and, at the same
time, will induce MDM2 expression, which in turn will inactivate p53 (40). However,
recent studies suggest that DNA damaging agents induce phosphorylation of p53 and
ATM-dependent phosphorylation of MDM2. The phosphorylated p53 and MDM2 are
incapable of mutual interaction (41-43).

MDM2 is an E3 ubiquitin ligase and can degrade p53: MDM2 degrades p53 by
targeting p53 to ubiquitination (44-47). However, mutants of MDM2 lacking the E3
ubiquitin ligase activity can efficiently bind with wild-type p53 and inhibit p53mediated transcriptional activation (29). This could be a cellular mechanism for
turnover of p53-MDM2 complexes. This view is also consistent with the fact that
MDM2 can bind and degrade many other proteins. MDM2 promotes its own
degradation (48), degradation of mutant p53 (49) and the growth suppressor ~ 1 4 1 ~ 1 9

ARF (SO). MDM2 binds and degrades the cell-fate protein "numb" (51). Also the
ubiquitin ligase activity is not required for MDM2-mediated tumorigenesis.

MDM2 interacts with several growth suppressors and other proteins: MDM2
interacts with several growth suppressors, including the tumor suppressor p53, the
retinoblastoma susceptibility gene product Rb and the growth suppressor p14 ARF.
These interactions are perceived as possible mechanisms for MDM2's oncogenic
function (reviewed in 52-58; 26-31,59-62).

MDM2 is induced by oncogenic challenges: Several oncogenic challenges
induce MDM2 in a p53-dependent or independent manner. Ionizing irradiation,
including y- and UV-irradiation and DNA damaging agents induce MDM2 expression
in a p53-dependent manner (33,62-64). UV irradiation also induces p53-nonbinding
forms of MDM2 (65). DNA-damaging aryl hydrocarbons induce MDM2 expression
in a p53-independent manner (66). Oncogenic Ras also induces MDM2 through the
Raf/MEK/MAP kinase pathway in a p53-independent manner (67). These findings
suggest that normal cells induce MDM2 in response to oncogenic challenges.

MDM2 induces G1 arrest in non-transformed cells: Considering all the evidence
for MDM2's oncogenic function, one would expect that overexpression of MDM2
would confer growth advantage in cultured cells. However, work from our laboratory
demonstrated that overexpression of MDM2 from its cDNA efficiently arrests the
growth of NIH3T3 cells (68). MDM2 accomplishes this in NIH3T3 cells by utilizing
two inhibitory domains, ID1 and ID2, that can independently arrest these cells at the
GO-Gl/S phase transition (68). Recently, two different laboratories have also reported
growth inhibitory functions of MDM2 (69,70). Consistent with these observations,

multiple laboratories have reported that overexpression of MDM2 is a favorable
prognostic marker in cancer (3,7 1-73).
The question arises therefore how to reconcile the growth-promoting and growtharresting properties of MDM2. Although overexpression of full-length MDM2 with its
functional inhibitory domains does not lead to development of antibiotic resistant
colonies expressing the protein in NIH3T3 cells, injection of nude mice with NIH3T3
cells stably expressing an MDM2 deletion mutant containing the N-terminal 1-130
amino acids, thus deleting the inhibitory domains, led to development of tumors at 616
sites injected. This suggests that MDM2 contains a tumorigenic domain located
within the N-terminal 1-130 amino acids. Interestingly, this growth-promoting
domain overlaps with the p53-interacting domain, enforcing the hypothesis that
MDM2 enhances tumorigenesis by inactivating p53. Since MDM2 can only be stably
expressed in cells harboring genetic defects such as H1299, this leads to the suggestion
that MDM2's normal function in the cell is to induce growth arrest, and inactivation of
the function of its inhibitory domains unleashes its tumorigenic potential.

Mechanisms of GI-S progression provide a control on cell growth. If MDM2
arrests cells at the GO-Gl/S phase transition, then cellular defects in one or more of
these mechanisms in cancer cells may create the cellular context for abrogation of
MDM2's normal growth suppressing functions and may promote the unmasking of its
tumorigenic ability. The pathway controlling progression from G1 into S phase
involves the retinoblastoma susceptibility protein Rb and the activity of cyclindependent kinases. Cyclins are induced sequentially in the cell division cycle and
associate with their partner kinases to promote progress through the cell cycle. Cyclin

D is first induced and associates with CDK416 to phosphorylate Rb at the restriction
point. Prior to this phosphorylation, the activity of cyclin DlCDK416 is restrained by

Figure 2. GI-S phase transtion. Components in the Rb pathway to regulate
progression through G I into S phase are shown. In panel 1, Rb is shown to bind at the
cyclin E promoter along with HDAC and Brgl and E2F to repress expression of cyclin E.
p16 inhibits cyclin D-CDK416 from phosphorylating Rb before the restriction point. In
panel 2, to enable cells to cross the restriction point thus committing the cell to a round of
DNA replication, cyclin D-CDK416 phosphorylates Rb, causing HDAC to disassociate
from Rb and enabling cyclin E to expressed from its promoter. In panel 3, the induced
cyclin E then associates to its kinase, CDK2, and this complex then further
phosphorylates Rb and Brgl as well, causing Brgl to leave and leading to induction of
cyclin A. Induction of cyclin A helps to initiate entry into S phase.

the cyclin-dependent kinase inhibitor p16, which provides a control to deregulated
progression through G1. Phosphorylation of Rb by cyclin D/CDK4/6 causes HDAC,
which was in association with Rb and Brgl to repress the cyclin E promoter, to
dissociate, leading to expression of cyclin E protein. Cyclin EICDK2 then further
phosphorylates Rb and Brgl, causing Brgl to leave Rb at the cyclin A promoter, thus
inducing expression of cyclin A whose activation of CDK2 is required to advance the
cell into DNA replication in S phase.
Cancer is the result of multiple genetic defects that lead to loss of control on cell
growth. Deregulation of GI-S progression and the process of DNA replication may
provide the cellular context that converts MDM2 from a growth suppressor to an
oncogene.

I. Chapter 2. Hypothesis
a. Major hypothesis.
The major hypothesis of this work involves deciphering the ways in which the
human oncoprotein MDM2 regulates cell growth. The objective was to (a) decipher the
ways in which MDM2 induces cell cycle arrest at the GO-Gl/S phase transition and (b)
determine novel interactions of MDM2 to further elucidate MDM2's complex cellular
functions. The hypothesis in (a) was based on the laboratory's previous observation that
MDM2 induces growth arrest at the GO-Gl/S phase transition in NIH3T3 cells. This is
accomplished in NIH3T3 through two inhibitory domains of MDM2, ID1 and ID2, which
are independently capable ot inducing arrest. Since MDM2 can only be stably expressed
in transformed cells such as H1299, and the function of MDM2 in normal cells is to
induce GO-Gl/S phase arrest when overexpressed, the hypothesis in (a) was that to
induce growth arrest MDM2 may be targeting one step in the GO-Gl/S progression,
while this function is disabled in cells harboring corresponding genetic defects. This
would suggest an explanation for the ability of some cancer cells to tolerate MDM2
overexpression. In part (b) the hypothesis was that since MDM2 has been shown to
interact with numerous proteins, proteomic analysis would reveal novel interacting
partners of MDM2 which could be validated by other methods.

b. Specific Aims.
The following were the specific aims: (1) To determine how MDM2 induces growth
arrest specifically in normal cells and suggest components of the pathway required for
this arrest; (2) To determine whether ID1 and ID2 arrest in G1 or inhibit DNA

replication; (3) To determine novel interacting partners of MDM2 through proteomic
analysis.

J. Chapter 3
MDM2 induces G1 arrest by down-regulating cyclin A through a mechanism
requiring the pl6lBrgl pathway.
The manuscript for the work presented in this chapter is currently in preparation.

a. Introduction.
Despite MDM2's well-established oncogenic potential, our laboratory has previously
shown that MDM2 overexpression is capable of inducing GO-Gl/S phase arrest. This is
accomplished in the immortalized cell line NIH3T3 through two inhibitory domains, ID1
and ID2. However, although the previous data showed cell cycle arrest using flow
cytometry, staining DNA to determine cell cycle phase using this method does not allow
for distinguishing whether the growth arrest is in GO, G1 or initiation into S, as the DNA
content in these phases should be similar. Therefore, we set out to determine the
mechanism of MDM2-mediated growth arrest by analyzing MDM2's effect on the
sequential induction of GI-S proteins as markers for the cell cycle step inhibited by
MDM2.

b. Experimental Results.
Expression of cyclin D, cyclin-D mediated phosphorylated Rb and cyclin E
is not affected by MDM2. Cyclins are induced in a sequential order as cells progress
through the cell cycle, and their expression is required to activate cyclin-dependent
kinases whose activity advances cells through the next step of the cell division cycle. If
MDM2 arrests the cell cycle at a point after a cyclin is induced, the induction of that
cyclin and the preceding cell cycle steps should be detected. Failure to detect expression
of an inducible cell cycle protein at the next step in the process would suggest the point at
which MDM2 overexpression is arresting cell cycle progression. Since the transfection

protocols available led to more cells being untransfected than transfected and extract
made from this population for Western blotting would reflect the average expression of
the endogenous protein levels of both MDM2 expressing and non-expressing cells, to
reliably detect the inhibited step we used flow cytometry. This method has the advantage
of separating transfected from untransfected cells and quantitating the level of the
endogenous protein being studied in each individual cell. To determine the growtharrested step, we looked for down-regulation of endogenous GI-S cyclins D, E and A as
well as phosphorylation of Rb at the restriction point by cyclin D-specific kinase in
response to MDM2 overexpression. We compared normal human lung fibroblast W138
cells capable of senescence, immortal murine fibroblast NIH3T3 and lung carcinoma
H1299 cells after transfection with MDM2 to determine any effect of added genetic
damage on MDM2's ability to arrest the cell cycle.
Since cyclin D is the first cyclin to be induced as cells enter GI, we first looked for
any change in level of expression of this cyclin in MDM2 expressing cells compared to
untransfected cells. MDM2 was detected using a phycoerythrin (PE)-coupled antibody,
while cyclin D was stained with a flourescein (F1TC)-coupled antibody. Transfected
MDM2-expressing cells were then separated from untransfected cells in a flow
cytometer, and a curve was generated to compare cyclin D levels between the two
populations based on FITC intensity. Figure 3 shows a representative detection of
transfected cells in W138 cells. Mock-transfected cells were stained with PE-anti-MDM2
and gated so that background staining in the MDM2-transfected sample using the same
gate would be represented at 0.1%. This PE staining of the mock sample encompasses
both endogenous MDM2 levels as well as non-specific staining. The mock cells were

also stained with a FITC isotype matched to the cyclin D antibody to show non-specific
binding so that staining of endogenous cyclin D in the transfected sample using the
specific antibody could be detected over background. Cells in the MDM2-transfected
sample that stained higher than background on the PE scale were taken as transfected ,
while staining of endogenous cyclin D can be seen as a shift to the right on the FITC
scale. This method was used for all of the following analyses.

transfected

I

Figure 3. Detection of transfected cells by flow cytometry. (A) Dot plot of mocktransfected W138 cells stained with PE-coupled anti-MDM2 antibody and FITC-coupled
IgG isotype of cyclin D antibody. The boundary of the mock-transfected cells was drawn
to achieve 0.1% background staining. (B) Detection of W138 cells successfully
transfected with MDM2 expression plasmid visualized by flow cytometry. The figure
shows a dot plot of W138 cells transfected with MDM2 expression plasmid and
imrnunostained with PE-coupled anti-MDM2 antibody and FITC-coupled cyclin D
antibody. MDM2-expressing cells are PE-labeled, and are indicated as "transfected. PEunlabeled cells from the same sample are shown as "untransfected". Transfected cells

overexpressed MDM2 and therefore are more intensely labeled with PE-coupled MDM2
antibody.

Comparison of the FITC-cyclin D curves in WI38, NIH3T3 and H1299 cells
generated in the above manner is shown in Figure 4. The figure plots cell count versus
FITC-cyclin D intensity, so the peak of each curve represents the maximum level of
cyclin D in the main cyclin D-expressing population, which should represent a
synchrony of cells at the same point in GI. Since transfected cells are shown to have
stained higher than isotype as seen in the middle panel, this suggests that cyclin D can be
detected in the transfected cells. Transfected and untransfected cells were taken from the
same plate and thus were stained in one tube under the same conditions; therefore, any
decrease in level of cyclin D in the transfected population in comparison to the
untransfected cells should indicate that MDM2 inhibits the cell cycle at the step of cyclin
D induction. However, comparison between MDM2-transfected and untransfected cells
shows that MDM2 does not alter the level of cyclin D in any of the three cell lines tested
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Figure 4. Cyclin D levels are not altered by MDM2 overexpression. MDM2transfected and untransfected W138 cells were gated and separated after staining with
a PE-coupled anti-MDM2 antibody, and the comparative FITC intensities of the cyclin
D-specific antibody transfected or untransfected cells are shown by a single parameter
histogram. The left panels show comparative FITC intensity of untransfected cells
stained with FITC-coupled cyclin D antibody and FITC-coupled IgG isotype. As
expected, the FITC-coupled anti-cyclin D antibody successfully detected cyclin D
expressing cells and stained cyclin D expressing cells more intensely than the FITCcoupled isotype. The middle panels show comparative staining of MDM2 transfected
cells stained with the cyclin D-coupled FITC antibody compared with cells stained
with FITC-coupled IgG isotype. In the case of both transfected and untransfected
cells, which were stained in the same population, cyclin D stained higher with the
specific antibody than the isotype antibody. The right panels show comparative FITC
intensity of transfected and untransfected cells stained with FITC-coupled cyclin D
antibody. In the case of W138 and H1299 cells (and NIH3T3 cells, not shown), there
was no difference in level of cyclin D between MDM2 and non-MDM2
overexpressing cells.

(NIH3T3 not shown), as there is no significant change in the position of the peaks. Since
cyclin D is expressed as cells enter GI, this suggests that the MDM2-mediated cell cycle
arrest shown previously by our laboratory (68) is not in GO and that MDM2 arrests the
cell cycle at a point after cyclin D induction.

Following cyclin D induction, cyclin D activates its associated kinase CDK416 which
then phosphorylates Rb at the restriction point. We therefore next checked for any
change in phosphorylation status of Rb by this specific cyclin/kinase complex using the
method described above. In Figure 5 , comparison of the peak intensity between
transfected and untransfected cells showed no change in status of cyclin D/kinasemediated phosphorylation of Rb by MDM2 overexpression in any of the three cell lines.
This suggests that MDM2 enables cells to cross the restriction point before exerting any
change on the cell cycle.
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Figure 5. Cyclin D-mediated phosphorylation of Rb levels are not latered by

MDM2 overexpression. Following the same analysis described for Figure 4, WI38,
NIH3T3 and H1299 cells were gated for MDM2-expressing and non-expressing cells,
and intensity of FITC was compared for staining with a FITC-coupled antibody
specific for cyclin D-mediated phosphorylated Rb. Transfected and untransfected cells

from the same population both stained more intensely than FITC-coupled isotype
antibody; however, there was no significant change in level of cyclin D-specific
phosphorylated Rb between these cells in response to MDM2 overexpression.
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Figure 6. Cyclin E levels are not altered by MDM2 overexpression. Following
the same analysis as in Figure 4, WI38, NIH3T3 and HI299 cells were gated to
separate the MDM2 and non-MDM2 overexpressing populations, and FITC intensity of
the anti-cyclin E antibody between these cells was compared. Transfected and
untransfected cells both stained higher for cyclin E-FITC levels than the matched FITC
isotype antibody; however, there was no significant decrease in level of cyclin E
mediated by MDM2 overexpression.
After phosphorylation of Rb at the restriction point, cyclin E is induced: so we next
looked for any effect of MDM2 on the cell cycle at the level of cyclin E induction.

However, MDM2 overexpression was found to cause no significant change in cyclin E
level in either WI38, NIH3T3 or H1299 cells (Figure 6). Therefore, MDM2 affects the
cell cycle at a point after cyclin E induction.

MDM2 overexpression down-regulates cyclin A in normal W138 cells. After
induction of cyclin E, the next cyclin to be expressed in the sequence is cyclin A which
enables cells to enter S phase, so we analyzed the three cell lines for any reduction in
cyclin A level mediated by overexpression of MDM2. Using the same method described
above, we stained MDM2 with a PE-coupled antibody and cyclin A with a FITC-coupled
antibody. The results in Figure 7 show that MDM2 overexpression in normal W138 cells
causes a significant (8)-fold reduction in cyclin A levels in comparison to untransfected
cells, suggesting that MDM2 acts on the cell cycle before S phase begins in these cells.
Down-regulation of cyclin A level by MDM2 in W138 cells was confirmed by confocal
nzicroscopy Figure 8. Using this method, we analyzed 50 MDM2-transfected
W138 cells, and all MDM2-overexpressing cells were found to lack expression of cyclin

A. By comparison, some untransfected cells in the same field were shown to express
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Figure 7. Cyclin A levels are down-regulated by MDM2 in W138 cells. MDM2
overexpressing and non-overexpressing cells were gated after staining with a PEcoupled anti-MDM2 antibody. The left panel shows imrnunostaining of untransfected

expressing MDM2 (FITC-stained) are shown by arrows, and cells expressing cyclin A
(rhodamine-stained) are shown by block arrows. Nuclei were stained with DAPI. All
cells expressing MDM2 lacked cyclin A expression.

Absence of endogenous MDM2 derepresses cyclin A expression. Our data
suggests that overexpression of MDM2 is capable of down-regulating cyclin A. We
therefore wanted to determine whether endogenous levels of MDM2 have a role in
regulating the expression of cyclin A. Since absence of MDM2 has been shown to
stabilize p53, and p53 can down-regulate cyclin A, instead of knocking down MDM2
with siRNA we compared endogenous cyclin A levels in normal, p53 knockout, and
p53IMDM2 double knockout MEFs to show an effect of MDM2 over that of p53. The
results in Figure 9 show that absence of p53 alone increases cyclin A level approximately
2-fold over normal MEFs, while knockout of MDM2 along with p53 increases
endogenous level of cyclin A 5-fold over normal MEFs. This suggests that endogenous
MDM2 levels contribute to repression of expression of cyclin A.
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Figure 9. Absence of MDM2 derepresses expression of cyclin A. To compare
level of cyclin A expression in normal, p53-I-, and p53-I-lMDM2-I- MEFs, the cells
were harvested and the pellet was boiled in equal volume of lammeli loading buffer.
Equal amounts of the extracts were subjected to SDS-PAGE and cyclin A detected with
an antibody purchased from Santa Cruz (SC-75 1).

MDM2 is unable to down-regulate cyclin A in NIH3T3 and HI299 cells. In contrast
to WI38, the cyclin A level in NIH3T3 or H1299 cells is not altered by overexpression of
MDM2. Figure 10 shows no significant difference in mean FITC-cyclin A intensity
between transfected and untransfected cells. Since NIH3T3 cells are immortal and H1299
are tumor-derived, this suggests that the cellular defects present in these cells allow them
to overcome this cell-cycle regulatory step mediated by MDM2.
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Figure 10. Cyclin A levels are unaffected by MDM2 overexpression in

NIH3T3 and HI299 cells. The figure compares level of FITC intensity of a cyclin Aspecific antibody in MDM2 transfected and untransfected cells, or each population
compared with a matched FITC-coupled IgG isotype. The left and middle panels show

staining of cyclin A expressing cells over nonspecific background binding to FITCcoupled IgG isotype of cyclin A antibody in untransfected and transfected cells,
respectively. The right panels show comparative expression of cyclin A in transfected
(MDM2-expressing, PE-labeled) and untransfected cells.

The N-terminal59-109 amino acids of MDM2 down-regulate cyclin A in W138
cells. The results above demonstrate that full-length MDM2 down-regulates cyclin A in
normal W138 cells while the same protein is uncapable of this function in NIH3T3 and
H1299, allowing them to advance past the point of cyclin A induction. Since full-length
MDM2 was previously shown by our laboratory to inhibit the cell cycle in GO-Gl/S in
NIH3T3 cells through the ID1 and ID2 domains (68) but our data shows that MDM2
allows NIH3T3 and H1299 to progress further through G1 than W138 before inducing
arrest, this suggests that MDM2 contains a third inhibitory domain that is disabled in the
defective cells. To locate this domain, we separately transfected a series of N- and Cterminal deletion mutants of MDM2 into WI38, and stained the fixed cells with both PEMDM2 and FITC-cyclin A antibodies to determine MDM2's effects on cyclin A levels as
described above. The results in Figure 11 show that a deletion mutant of MDM2, MDM2
1-109 containing the N-terminal 109 amino acids, is capable of down-regulating cyclin A
levels in W138 to an extent similar to the wild-type protein. To further define the
required domain, we used another MDM2 deletion mutant that contains amino acids 59220 and found that on deletion of the N-terminal58 amino acids, MDM2 retains its
ability to down-regulate cyclin A. This further defines the cyclin A-inhibitory domain
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Figure 11. The N-terminall-109 amino acids of MDM2 down-regulate
cyclin A. The left panels shows irnmunostaining of untransfected W138 cells with
FITC-coupled anti-cyclin A antibody over background staining with FITC-coupled
IgG isotype of cyclin A antibody. Comparative expression of cyclin A in MDM2 del
491-1 10 transfected (curve 3) and untransfected (curve 2) W138 cells is also shown.

to amino acids 59-109 of MDM2. Since our laboratory had previously demonstrated that
deletion of the N-terminal58 amino acids, which is in the p53-binding domain of
MDM2, eliminates MDM2's ability to interact with p53 (29), the data in Figure 12 also
suggests that the MDM2-p53 interaction is not required for MDM2 to down-regulate
cyclin A.

The cyclin A inhibitory domain of MDM2 induces G1 arrest in normal W138
cells but not tumor-derived H1299. Since MDM2 inhibits expression of cyclin A in
normal but not tumor-derived cells, and induction of cyclin A is required for entry into S
phase, we hypothesized that transfection of the MDM2 1-109 deletion mutant into W138
should lead to G1 arrest, while having no effect in H1299. To test this, we transfected
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Figure 12. Deletion of the N-terminall-58 amino acids of MDM2 does not
abrogate cyclin A down-regulationby MDM2. The top panel shows the domains of
MDM2 overlapping with the cyclin A inhibitory domain. The left lower and middle
panels compare anti-cyclin A-PE staining of untransfected and MDM2 59-220
transfected W138 cells with a matched PE-coupled isotype, respectively. The lower
right panel compares cyclin A PE intensity of MDM2 transfected and untransfected
cells. The boxed middle panel shows further definition of the cyclin A inhibitory
domain of MDM2 to amino acids 58-109.
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Figure 13. The N-terminall-109 amino acids of MDM2 induce G1 arrest in
normal WI38 cells but not tumor-derived HI299 cells. W138 and H1299 cells were
transfected with MDM2 del491-110 and MDM2 was stained in the fixed cells with an
FITC-coupled antibody and DNA was stained with either PI or 7AAD. Panel A shows
mock-transfected W138 cells stained with the MDM2-FITC antibody with a gate drawn
to achieve 0.1 % background staining. Panel B shows detection of MDM2 del49 1- 110transfected W138 that stain in this gate. Panel C and D show DNA histograms of
untransfected and MDM2 del491- 110 transfected WI38 and H1299 cells, respectively.

MDM2 1-109 into both W138 and H1299 cells and stained the fixed cells with a FITCMDM2 antibody and DNA with either propidium iodide (PI) or 7-aminoactinomycin D
(7AAD) to obtain a DNA histogram. A representative gating of MDM2-expressing
FITC-labeled cells over mock-transfected background in W138 cells is shown in Figure
13 panels A and B. Generation of a DNA histogram overlay of the transfected and
untransfected populations showed that MDM2 1-109 led to G1 arrest in W138 but not
H1299, consistant with the previous finding that MDM2 down-regulates cyclin A in
normal but not tumor-derived cells, Figure 11 panels C and D. This suggests that the
domain situated within the N-terminal 1-109 amino acids of MDM2 that is able to downregulate cyclin A is also capable of inducing G1 arrest in normal cells.

The N-terminall-109 amino acids of MDM2 induce G1 arrest by downregulating cyclin A. If the G1 arrest induced by the MDM2 1-109 domain is a result of
MDM2 down-regulating cyclin A, forced expression of cyclin A in the presence of the
MDM2 1-109 expression product should permit cells to bypass the inhibited step. To test
this, we co-transfected MDM2 1-109 and cyclin A expression plasmids into W138 cells
in which MDM2 normally down-regulates cyclin A, and compared the DNA histograms
of the untransfected cells with those positive for both MDM2 and cyclin A expression. In
this experiment, MDM2 was labeled with a PE-coupled antibody, while cyclin A was
stained with FITC and DNA was labeled with 7AAD. Figure 14 panel A shows downregulation of cyclin A by 1-109 expression alone, while panel C shows that the level of
cyclin A in the co-transfected cells is similar to endogenous cyclin A levels in the
untransfected population. Comparison of the histograms of untransfected and MDM2 1109lcyclin A co-expressing cells in panel D demonstrates that when cyclin A is co-
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Figure 14. MDM2 induces G1 arrest by down-regulatingcyclin A. Comparison
of cyclin A levels (A, C) and DNA histograms (B, D) of untransfected cells with that of
MDM2 Del491-110 expression plasrnid transfected (A, B), and MDM2 Del491-110
and cyclin A expression plasmids cotransfected (C, D) W138 cells.

expressed with MDM2 1- 109, the growth inhibition caused by the 1-109 domain alone
(panel B) is overcome and cells no longer arrest in G1. This data links the G1 arrest
function of the MDM2 1-109 domain with this domain's ability to down-regulate cyclin
A.

MDM2 requires cyclin-dependent kinase inhibitor p16 to down-regulate cyclin A.
We wished to investigate the mechanism for down-regulation of cyclin A by MDM2.
One common cellular defect in cancer is lack of expression of the cyclin-dependent
kinase inhibitor p16, whose expression is deregulated in greater than 30% of human

Figure 15. Specific silencing of p16 by siRNA. Silencing of p16 in W138 extracts
after transfection with 80 pmol of specific siRNA is compared by Western blot with
equal loading of W138 extracts transfected with 80 pmol of scrambled siRNA.

cancers. It is known that NIH3T3 cells contain deleted p16 gene, while in H1299 the p16
gene is methylated, preventing expression of the protein. Since absence of expression of
p16 is common to both of these cell lines in which MDM2 cannot down-regulate cyclin
A, and p16 regulates the pathway leading to cyclin A expression, we wanted to determine
whether MDM2 requires p16 to down-regulate cyclin A. To accomplish this, we turned
to a p16 siRNA system. Figure 15 shows knockdown of p16 protein expression in W138
cells by Western blot. We then plated W138 cells onto coverslips after tranfection with
MDM2 and either scrambled or p16 siRNA, and stained MDM2 and cyclin A for analysis
by confocal microscopy. Figure 16 shows that transfection of MDM2 with scrambled
siRNA does not alter MDM2's ability to down-regulate cyclin A. However, when
MDM2 is co-transfected with p16 siRNA, MDM2 loses its ability to down-regulate

other genes whose promoters have been methylated as well. Since we have demonstrated
that silencing of p16 prevents MDM2 from down-regulating cyclin A in W138 cells, and
MDM2 cannot down-regulate cyclin A in H1299, we hypothesized that treatment of
H1299 cells with azacytidine should re-enable this function of MDM2 in this cell line.
To test this hypothesis, we analyzed MDM2's ability to decrease the percent of cyclin A
expressing cells using flow cytometry or lower luciferase activity from the cyclin A
promoter in HI299 cells treated with azacytidine compared to buffer treatment alone.
The results in Figure 18 part A show that azacytidine treatment enables MDM2
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Figure 18. Treatment of H1299 cells with 5-aza-deoxycytidine partially restores
the ability of MDM2 to regulate cyclin A expression in HI299 cells. Ability of
MDM2 Del491-110 (A) to inhibit cyclin A expression, and (B) to inhibit cyclin A

promoter activity can be reinforced in HI299 cells by re-expressing endogenous p16 after
5-aza-2'-deoxycytidine treatment. Reinduction of p16 after treatment with 5-aza-2'deoxycytidine is shown by Western. Expression of MDM2 del491-110 is also shown.
(A) Percent of cyclin A expressing cells in MDM2 Del491-110 expression plasrnid
transfected and untransfected population after buffer- or 5-aza-2'-deoxycytidinetreatment are shown by a bar graph. Cyclin A expression in H1299 cells was determined
by a FITC-coupled anti-cyclin A antibody, and MDM2 Del49 1- 110 expression was
detected by a PE-coupled anti-MDM2 antibody. (B) Cyclin A promoter activity was

.

determined by assaying expression of luciferase from a luciferase reporter plasmid under
the control of cyclin A promoter. For transfection of buffer-treated and 5-aza-2'deoxycyctidine-treated-cells,200 ng of a cyclin A luciferase reporter plasmid and 2 pg of

pCMVMDM2 expression plasmids were used.

Del491-110 to reduce the percent of cyclin A expressing cells to a greater extent than
azacytidine treatment or MDM2 transfection alone. Similarly in Figure 18 part B, this
trend was evidenced by decreased luciferase activity from the cyclin A promoter in
MDM2 transfected cells treated with azacytidine in comparison to azacytidine treatment
or MDM2 expression alone. These data suggest that treatment of H1299 cells with
azacytidine partially restores the ability of MDM2 to down-regulate cyclin A.

MDM2 reduces expression from a cyclin A reporter gene when cotransfected
with p16 in HI299 cells. Since azacytidine treatment is not specific for demethylation of
the p16 gene, we wished to confirm that the effects on cyclin A expression by MDM2 in
the preceding data was due to reinduction of p16 and not global demethylation.

Therefore, we cotransfected H1299 cells with a cyclin A-luciferase reporter construct and
MDM2 and p16 plasmids, or with either vector, MDM2 or p16 plasrnids alone, and
compared the luciferase activity of the extracts. Figure 19 shows that MDM21p16
cotransfection reduces luciferase activity from the cyclin A promoter approximately 4fold over p16 transfection alone, and 6-fold over MDM2 transfection and 3-fold over
vector alone. This suggests that re-expression of p16 partially restores MDM2-mediated
down-regulation of cyclin A in HI299 cells.
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Figure 19. Cotransfection of p16 with MDM2 enables MDM2 to inhibit
expression from a cyclin A reporter plasmid. MDM2 inhibits the cyclin A
promoter after re-expressing p16 in H1299 cells by using a p16 expression plasmid.
H1299 cells were transfected with 400 ng of a cyclin A luciferase reporter plasmid in
the presence or absence of 100 ng pCMV p16 or 400 ng pCMV MDM2 expression
plasmids. Luciferase activity of cell extracts containing equal amounts of proteins was
determined 24 hours after transfection, shown in the left panel. The right panel shows
expression of p16 and MDM2 determined by Western blot analysis. Additions of
expression plasmids during transfection are shown in the figure. Migration of p16,
MDM2 and P-actin are indicated by arrows.

MDM2 requires Brgl to down-regulate cyclin A. Another component in the p16dependent pathway to control cyclin A expression is Brgl, part of the chromatin
remodeling SWVSNF complex, which remains bound to Rb until its phosphorylation by
cyclin Elcdk2 causes it to leave, thus leading to derepression of cyclin A expression.
Since phospliorylation of Brgl is accomplished by cyclin Elcdk2, and MDM2 inhibits the
cell cycle at a point after cyclin E induction, we checked the requirement of Brgl in the
mechanism for MDM2 to down-regulate cyclin A. After transfectioii of W138 cells with
MDM2 and either scrambled or Brgl siRNA, we stained MDM2 with a FITC-coupled
antibody and cyclin A with an antibody coupled to rhodamine and analyzed the cells by
confocal microscopy. Staining of Brgl in Figure 20 part B shows that Brgl levels were
down-regulated by the specific siRNA in comparison to scrambled siRNA (Figure 20
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Figure 20. MDM2 requires Brgl to down-regulate cyclin A. Panel A shows
detectin of Brgl in the nucleus after transfection with scrambled siRNA, while Panel B
shows that transfection with Brgl siRNA downregulates this protein in W138 cells.
Panel C shows the ability of MDM2 to down-regulate cyclin A after transfection with
scrambled siRNA in WI38 cells (shown by arrows). Panel D shows that after
transfection of WI38 cells with Brgl siRNA, MDM2 loses its ability to down-regulate
cyclin A. MDM2 was stained with a FITC-coupled antibody (N20, Santa Cruz), and
cyclin A was stained with an antibody purchased from Santa Cruz (SC751 TRITC).
The antibody used to detect Brgl was purchased from Santa Cruz (SC-17796) followed
by staining with a rhodamine goat anti-mouse secondary antibody from Jackson
Irnmunoresearch (1 15-295-146). DAPI was used to stain nuclei.

part A) when visualized using the same settings by confocal microscopy. The data in
Figure 20 part D demonstrate that in the MDM2/Brgl siRNA transfected cells, MDM2
loses its ability to down-regulate cyclin A, while MDM2 in the scrambled siRNA
cotransfected cells retains this function (Figure 20 part C). This data in conjunction with
the preceding p16 data suggests that MDM2 functions to down-regulate cyclin A
dependent on the pl6/Brgl pathway.

c. Chapter Summary.
To determine one pathway by which MDM2 induces growth arrest, we analyzed
progression of the cell cycle in MDM2-arrested cells to find the inhibited step by
detecting the sequential induction of proteins involved in transition from G1 into S phase.

Flow cytometric analysis in WI38, NIH3T3 and H1299 cells showed no change to cyclin
D, cyclin D-mediated phosphorylated Rb, or cyclin E levels in response to MDM2
overexpression, suggesting that the point of inhibition is at a point later than these
cellular events. However, MDM2 overexpression was found to down-regulate cyclin A
in normal W138 cells while affecting no change to this cyclin in immortal NIH3T3 or
tumor-derived H1299 cells. The domain responsible for cyclin A down-regulation is
located within amino acids 59-109 of MDM2. Absence of endogenous MDM2
derepresses cyclin A levels in MEFs, suggesting that endogenous MDM2 levels as well
as MDM2 overexpression assist in down-regulating cyclin A expression. MDM2 induces
G1 arrest by down-regulating cyclin A, which is expected since cyclin A is required for
entry into S phase. Silencing of p16 prevents MDM2 from inhibiting cyclin A expression
in WI38, while reinduction of p16 partially restores this function of MDM2 in H1299
cells. Down-regulation of cyclin A is also eliminated by absence of Brgl in WI38.
These data suggest that MDM2 functions to inhibit expression of cyclin A through the
pl6lBrgl pathway. Since absence of p l 6 expression is a common defect in human
cancer, this also suggests one mechanistic pathway by which MDM2 is converted from a
growth inhibitor to a potentially oncogenic protein.

K. Chapter 4.
Inhibitory domain 2 (ID2) of MDM2 arrests the cell cycle by inhibiting DNA
replication.
The manuscript for the work presented in this chapter is currently in preparation.

a. Introduction.
Previous work from our laboratory using flow cytometry showed that MDM2 arrests
the cell cycle in NIH3T3 cells through two inhibitory domains ID1 and ID2 that function
in this cell line to arrest the cell cycle at the GOIG1-S phase transition (68). The data
presented in the preceding chapter demonstrates that a third inhibitory domain located
between amino acids 59-109 of MDM2 induces G1 arrest by down-regulating cyclin A in
cells that have a functional pl6lBrgl pathway. Since induction of cyclin A is one of the
events that initiates entry into S phase but ID1 and ID2 inhibit cell cycle progression at a
step downstream of cyclin A induction, we hypothesized that these inhibitory domains
may target cells for arrest at a point prior or later than replication initiation and wanted to
determine the significance of MDM2 overexpression in the absence of cyclin A downregulation in an immortal or tumor-derived cellular context.

b. Experimental results.
A deletion mutant containing the N-terminall-109 amino acids of MDM2
prevents DNA replication in cells that respond to the cyclin A down-regulatory
function of this domain. Replication of DNA can be detected using a
bromodeoxyuridine (BrdU) assay. BrdU is a thymidine analog that is incorporated into
DNA as replication proceeds. Detection of incorporated BrdU using a flourescentlylabeled antibody therefore provides a way to determine whether MDM2 overexpfession
enables cells to enter S phase. To determine the ability of MDM2's inhibitory domains to
prevent entry into S phase, we transfected normal WI38, immortal NIH3T3, and tumor-

derived H1299 cells with MDM2 or its deletion mutants. Forty-eight hours after
transfection, cells were labeled with BrdU to detect replication status and the cells were
harvested and fixed. MDM2 was stained with a PE-coupled antibody while BrdU was
labeled with a FITC-coupled antibody, and DNA was stained with 7-AAD. Transfected
and untransfected cells were gated and analyzed by flow cytometry. The difference
between the percent of transfected or untransfected cells from the same population that
incorporated BrdU indicated the ability of the inhibitory domains of MDM2 to inhibit
DNA replication. The results in Figure 21 show a representative experiment using
MDM2 del491-110 transfected into W138 cells. The gates were drawn so that
background staining from the FITC-coupled anti-BrdU antibody in cells that were not
subjected to BrdU treatment was 0.1% or less. Cells from the untransfected population
that labeled as BrdU positive on the FITC scale are shown in the M gate in Figure 21 part
A to be 29.0%, while BrdU negative cells in the L gate are 67.5%. In comparison, only
7.7% of MDM2 del49 1-110 transfected cells in the M gate in Figure 2 1 part B are
labeled as BrdU positive, while 91.1% of the cells in the L gate are BrdU negative. This

A.

B.
Untransfected

MDM2 del 491-1 10 transfected

m
19

5f:
C3
0

-1
U

03

m

.

.

---

.

---4

4

i

E

.1

FITC L O G

1000

E

I 11111.

-1

I 11111.

I 1 1 1 1 1 ~ I I I I I ~

FITC L O G

1808

Figure 21. Detection of BrdU positive cells by flow cytometry. MDM2 del491110 transfected and untransfected cells from the same population were labeled with
BrdU and were harvested and fixed. Panel A shows detection of cells that were
actively incorporating BrdU in the untransfected population in the M gate (29%),
versus cells that did not incorporate BrdU in the L gate (67.5%). MDM2 del491-110
cells separated from the untransfected population are shown in Panel B to have only
7.7% of the transfected cells actively incorporating BrdU using the same gate.

suggests that MDM2 del491-110 prevents entry into S phase in W138 cells as expected
since this deletion mutant harbors the inhibitory domain that down-regulates cyclin A.
Similarly, we transfected NIH3T3 and H1299 cells with this deletion mutant and
analyzed the cells using the same method. The results for all three cell lines are
summarized in Figure 22. The data shows that in both NIH3T3 and H1299, MDM2 del
491-1 10 does not have the ability to inhibit DNA replication, as there is no significant
difference between BrdU incorporation in transfected and untranfected cells. This
corresponds with the finding in the preceding chapter that the inhibitory domain
contained within this region of MDM2 down-regulates the S-phase initiating factor cyclin
A in W138 cells while losing this function in the context of NIH3T3 and H1299 cells.

Percent BrdU positive cells
MDM2( )
MDM2( + )
W138 -- 27.1
6.4
34.1
NIH3T3 -- 29.8
41.9
HI299 -- 35.4

-

Figure 22. Effects of the N-terminall-109 amino acids of MDM2 on BrdU
incorporation. The cyclin A inhibitory domain inhibits DNA replication only in W138
cells but not in NIH3T3 or H1299 cells. The chart shows percentage of untransfected
cells or transfected cells expressing MDM2 or MDM2 Del49 1-110 actively
incorporating BrdU. Cells expressing MDM2 or MDM2 Del491-110 were detected by
PE-coupled anti-MDM2 antibody. FITC-coupled anti-BrdU antibody was used to
detect BrdU incorporating cells.

The N-terminall-154 amino acids of MDM2 inhibit replication in W138 but not
NIH3T3 or HI299 cells. We next tested the ability of MDM2 del491-155 to induce a
block to replication in WI38, NIH3T3 and H1299 cells. Since this deletion mutant
harbors the cyclin A inhibitory domain but not ID1 or ID2 we expected similar results in
the three cell lines as was obtained with MDM2 de1491-110. As expected, MDM2 del
49 1- 155 was capable of efficiently preventing BrdU incorporation in W138 but not
NIH3T3 or H1299, as shown in Figure 23.

Percent BrdU positive cells
MDM2( - )
MDM2(+ 1
W138 -35.3
10.3
NIH3T3 -30.8
26.6
HI299 -37.2
19.6

Figure 23. Effects of the N-terminall-154 amino acids of MDM2 on BrdU
incorporation. The deletion mutant MDM2 del491-155 does not alter the effects on
BrdU incorporation compared to MDM2 del491-110. BrdU and MDM2 were detected
as described in Figure 22.

The N-terminal 1-220 amino acids of MDM2 containing the cyclin A inhibitory
domain and ID1 inhibit BrdU incorporation efficiently in W138 but not NIH3T3 or
HI299 cells. Previous data from our laboratory suggested that the growth of NIH3T3
cells is arrested by MDM2 overexpression through two inhibitory domains that are
functional in these cells, ID1 and ID2, which can independently arrest the cell cycle at the
GO-Gl/S phase transition. We therefore wanted to determine whether the deletion
mutant MDM2 del491-221 containing functional ID1 could inhibit BrdU incorporation
in NIH3T3 and thus entry into S phase. We transfected this deletion mutant into W138
and H1299 cells as well to determine its effect in these two cell lines. The results in
Figure 24 show that this deletion mutant harboring ID1 along with the cyclin A inhibitory
domain prevents BrdU incorporation in W138 to a similar extent in these cells as the
MDM2 del491-110 deletion mutant containing the cyclin A inhibitory domain alone.
However, in NIH3T3 and H1299 cells MDM2 del491-221 does not significantly
decrease the percent of BrdU positive cells in response to MDM2 overexpression
compared to untransfected cells, suggesting that this deletion mutant does not inhibit
initiation to DNA replication in NIH3T3 or H1299. Prior data from the laboratory
demonstrated that MDM2 del491-221 expression leads to GO-Gl/S arrest in NIH3T3
through ID1, although inefficiently, while elimination of the N-terminal58 amino acids

from this deletion mutant increases the efficiency similar to the extent seen with the fulllength protein in this cell line. To determine whether the N-terminal58 amino acids
interfere with the ability of ID1 to inhibit BrdU incorporation requires further BrdU
incorporation experiments using MDM2 59-221. Previous data from the laboratory
suggests that MDM2 del491-221 cannot be expressed stably in NIH3T3 (68), suggesting
that inclusive of the contribution from the N-terminal58 amino acids, ID1 is inhibitory to
the growth of NIH3T3 cells.

Percent BrdU positive cells
MDM2( - )
MDM2 ( + 1
W138 -31.1
10.4
NIH3T3-37.1
26.9
38.6
20.1
HI299 --

Figure 24. Effects of the N-terminall-220 amino acids of MDM2 on BrdU
incorporation. A deletion mutant MDM2 del491-221 including ID1 along with the
cyclin A inhibitory domain does not significantly inhibit BrdU incorporation in
NIH3T3 or H1299 cells but maintains an inhibition to BrdU incorporation in W138
similar to MDM2 del49 1-110 or MDM2 de149 1- 154. BrdU and MDM2 were detected
as described in Figure 22.

Overexpression of full-length MDM2 inhibits BrdU incorporation in WI38,

NIH3T3 and HI299 cells. We finally tested full-length MDM2 in WI38, NIH3T3 and
H1299 cells for whether presence of ID2 would lead to an inhibition of replication in
H1299 or NIH3T3 which incorporate BrdU to the same extent as untransfected cells
when overexpressing deletion mutants of MDM2 containing ID1 or the cyclin A
inhibitory domain. The results summarized in Figure 25 show that full-length MDM2
overexpression in NIH3T3 and H1299 cells inhibits BrdU incorporation as efficiently as
it does in WI38. Since ID1 and ID2 both arrest the GO-GI-S phase transition by DNA
histogram in NIH3T3 but ID2 prevents BrdU incorporation in this cell line with
apparantly minimal effect to this process contibuted by ID1, this suggests that ID2
functions as the replication inhibitory domain, while ID1 may function after replication
initiation in the full-length protein, possibly by inhibiting elongation of the DNA strand.
Further experiments need to be done to confirm this hypothesis.

Percent BrdU positive cells
MDM2 ( )
MDM2(+)
W138 -- 20.2
7.2
NIH3T3-- 25.4
9.3
HI299 -- 36.2
7.0

-

Figure 25. Effects of full-length MDM2 on BrdU incorporation. The percent
of Brdu positive cells is shown in MDM2 overexpressing and non-overexpressing
WI38, NIH3T3 and HI299 cells. Inclusion of ID2 enables NIH3T3 and H1299 cells to
prevent BrdU incorporation to a similar extent as W138 cells. BrdU and MDM2 were
detected as described in Figure 22.

Accumulation of cellular mutations desensitizes cells to growth arrest mediated
by MDM2. The preceding data demonstrates that the N-terminal 1-109 amino acids of
MDM2 prevent BrdU incorporation in normal W138 cells but not immortal NIH3T3 or
tumor-derived H1299, which is expected since this domain is capable of inhibiting
expression of cyclin A in W138 but not NIH3T3 or H1299. However the BrdU
incorporation experiments in this chapter in conjunction with the data in Chapter 3
suggest that ID2 functions to inhibit DNA replication downsteam of cyclin A induction
while ID1 apparantly functions downstream of replication initiation. The data presented
in Chapter 3 shows that cellular defects such as p16, Brgl or p53 deficiency abrogate the
ability of the N-terminal59- 109 amino acids of MDM2 to downregulate cyclin A and
lead to G1 arrest, and suggests that further cellular damages may contribute to the
inactivation of the other inhibitory domains ID1 and ID2. We therefore wanted to assay
the significance of MDM2 overexpression in the three different cell types to determine
whether a normal, immortal or tumor-derived cellular context has any consequence for
the ability of MDM2's inhibitory domains to arrest cell growth. The results in Figure 26
compare the ability of full-length MDM2 containing the three functional inhibitory
domains or a deletion mutant MDM2 del 1-120 that contains only ID1 and ID2 to induce

GI arrest in W138 cells after transfection with 500 ng of either DNA. Both MDM2 and
MDM2 del 1-120 led to a similar percent increase in the number of cells in GI, 18.9%
and 15.7%, respectively, from the number of untransfected cells from the same
population. MDM2 overexpression from 500 ng of plasmid DNA resulted in growth
arrest with 77.5% of transfected cells in GI, while MDM2 del 1-120 expression from 500
ng of plasmid DNA led to 81% of transfected cells in GI. This suggests that the cyclin A
inhibitory domain in full-length MDM2 and ID1 and ID2 present in the MDM2 del 1-120
deletion mutant can induce growth arrest in normal W138 cells to a similar extent when
MDM2 is expressed from 500 ng of plasmid DNA, suggesting that dysfunction of the
pathway utilized by the cyclin A inhibitory domain does not have consequence for the
ability of MDM2 to induce growth arrest through ID1 and ID2 in the absence of other
cellular defects at this level of expression.

Figure 26. Comparison of the ability of full-length MDM2 and a deletion
mutant of MDM2 harboring ID1 and ID2 to induce G1 arrest in WI38 cells. Fulllength MDM2 and MDM2 del 1-120 were transfected using 500 ng of either DNA into
W138 cells. Forty-eight hours after transfection the cells were harvested and fixed.
MDM2 was stained with 2A10 (courtesy of Arnold Levine) followed by staining with
an anti-mouse IgG (goat) fluorescein conjugated secondary antibody (Calbiochem
DC13L). DNA was stained with PI and DNA histograms generated after analysis by
flow cytometry. Percent increase in GI cells by MDM2 represents the difference in the
percent of MDM2-expressing cells in GI in comparison to the percent of cells in GI in
the untransfected population from the same experiment. For the full-length MDM2
experiment the standard devation for transfected cells in GI was 2.52% while for
untransfected cells the standard deviation was 0.234%. For the MDM2 del 1-120
experiment the standard deviation for transfected cells in G I was 2.0% while for
untransfected cells it was 0.167%.
In NIH3T3 and H1299 cells, the cyclin A inhibitory domain is not functional, but
NIH3T3 is known to induce growth arrest through ID1 and ID2 (68) while we have
shown in this chapter that H1299 cells do not incorporate BrdU in the presence of ID2
when full-length MDM2 is expressed from 5 ug of plasrnid DNA. We therefore wanted
to determine whether the defects present in immortal NIH3T3 would desensitize these
cells to MDM2-mediated GlIS arrest and whether tumor-derived H1299 cells would be
further desensitized in the context of their more extensive mutations. To test this, we
transfected these cells with 500 ng of MDM2 and compared the ability of MDM2 to
increase the number of G1 cells in the different cell types. Figure 27 shows that MDM2

expressed from 500 ng of plasmid has a decreasing ability to arrest at GlIS in cells with
increasing genetic damage. While MDM2 expressed at this level increases the percent of
GI cells by 18.9% in normal W138 cells, this number is decreased to 15.3% in immortal
NIH3T3 and is decreased to 6.7% in tumor-derived H1299. To show this difference

Figure 27. Increasing amounts of cellular mutations lead to desensitivity for
the growth-arrest function of MDM2 WI38, NIH3T3 and H1299 cells were
transfected with different concentrations of MDM2 DNA shown in the bar graph.
Forty-eight hours after transfection the cells were harvested and fixed, and MDM2 was
stained with 2A10 (provided by Arnold Levine) followed by a anti-mouse IgG (goat)
fluorescein conjugated secondary antibody (Calbiochem DC13L). DNA was stained
with PI and DNA histograms were generated by flow cytometry. The percent of cells
in GI was estimated by using a modfit program. Percent increase in G1 cells by
MDM2 represents the difference in the percent of MDM2-expressing cells in G1 in

comparison to the percent of cells in GI in the untransfected population from the same
experiment. For the 250 ng experiment in W138 the standard devation for transfected
cells in G1 was 1.74% while for untransfected cells the standard deviation was 0.132%.
For the 500 ng experiment in W138 the standard devation for transfected cells in G1
was 2.52% while for untransfected cells the standard deviation was 0.234%. For the 1 pg
experiment in W138 the standard deviation for transfected cells in G1 was 1.12% while
for untransfected cells it was 0.232%. For the 250 ng NIH3T3 experiment the standard
deviation for transfected cells in G1 was 1.23% while for untransfected cells it was

0.229%. For the 500 ng NIH3T3 experiment the standard deviation for transfected cells
in G1 was 1.33% while for untransfected cells it was 0.309%. For the 500 ng H1299
experiment the standard deviation for transfected cells in G1 was 1.23% while for
untransfected cells it was 0.332%. For the 1 pg H1299 experiment the standard deviation
for transfected cells in G1 was 2.46% while for untransfected cells it was 0.342% For the

2 pg H1299 experiment the standard deviation for transfected cells in GI was 1.16%
while for untransfected cells it was 0.252%

further between W138 and NIH3T3, we transfected both with 250 ng of MDM2 and
found that while MDM2 retains the ability to increase the number of G1 cells by 15.4%,
this is dramatically lowered in NIH3T3 to 8.5%. Even more MDM2 was required to
achieve efficient GlIS arrest in H1299 similar to WI38, as transfection with 1 pg of

MDM2 increased the number of G11S cells in H1299 by 20% while a comparable effect
could be obtained in W138 (18.9%) using only 500 ng of plasmid. Transfection with 2 pg
of MDM2 increased the efficiency of GIIS arrest in H1299, consistent with this trend.

These data demonstrate a cell-type variation in response to MDM2 overexpression,
suggesting that increasing amounts of cellular mutations lead to desensitivity for the
growth-arrest function of MDM2.

Chapter summary.
To determine whether ID1 and ID2 arrest the cell cycle in G1 or S phase, we
employed BrdU incorporation assays in WI38, NIH3T3 and H1299 cells. Experiments
using overexpression of the N-terminal 1-109 amino acids of MDM2 in the three cell
lines supported the data in Chapter 3 that MDM2 induces G1 arrest by down-regulating
cyclin A only in normal cells, as this deletion mutant harboring the cyclin A inhibitory
domain was capable of preventing BrdU incorporation only in W138 cells, and not
NIH3T3 or H1299. A deletion mutant containing the N-terminal 1-154 amino acids of
MDM2 did not alter this effect. MDM2 del491-221 containing the cyclin A inhibitory
domain and ID1 did not significantly decrease the percent of BrdU positive cells in
NIH3T3 or H1299 cells, suggesting that this deletion mutant does not inhibit initiation to
DNA replication in NIH3T3 or H1299 cells. However, overexpression of full-length
MDM2 was capable of inhibiting BrdU incorporation in NIH3T3 and H1299 to a similar
extent as in W138 cells. This suggests that ID2 is the DNA replication inhibitory domain.
Flow cytometric analysis of different concentrations of MDM2 transfected into the three
cell lines showed that MDM2 is capable of inducing G1 arrest at lower levels of
expression in normal cells, and increasingly higher levels of expression are required for
similar efficiency in G1 arrest in cells with increasing levels of genetic damage. This
suggests that added genetic damage leads to toleration of MDM2 overexpression in
cancer cells.

L. Chapter 5.
MDM2 interacting partners: MDM2 interacts with the translation elongation
factor efl-a.
The manuscript for the work presented in this chapter is currently in preparation.

a. Introduction.
Although MDM2's interaction with the tumor suppressor p53 is considered to be the
most important, MDM2 interacts with several other proteins involved in cell growth
regulation. These interactions include tumor suppressors Rb and pl4ARF, as well as
E2FlIDP1, TATA-binding protein, spl, DNA polymerase epsilon, and SV40 T antigen.
MDM2 also interacts with its related protein MDMX and ribosomal proteins L5, L11 and
L23. To determine novel interacting partners of MDM2, we performed proteomic
analysis of MDM2 overexpressed in the tumor-derived cell line H1299 in an attempt to
gain more insight into the diversity of MDM2's cellular functions.

b. Experimental Results.
Proteomic analysis of MDM2 expressed in HI299 cells. The tumor-derived human
lung carcinoma cell line H1299 was chosen for proteomic analysis due to its high
transfection efficiency using the methods available in the laboratory, which would
facilitate detecting MDM2-associated protein complexes. For this purpose, H1299 cells
were transfected with either vector or MDM2 plasmids, and the cells were fractionated
into cytoplasmic and nuclear fractions. After immunoprecipitation with an anti-MDM2
antibody to pull down MDM2-associated proteins, the beads were eluted and
subsequently sent for proteomic analysis. The results in Table 1 show the proteins found
to be in complex with MDM2 in the nuclear and cytoplasmic fractions. This analysis
confirms MDM2 interactions already identified in the literature, such as ribosomal
proteins L5, L23 and L l l . Among the other proteins identified in Table 1,
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Table 1. MDM2 interacting proteins in HI299 cells.
Nuclear fraction
ribosomal protein L5
ribosomal protein L23
ribosomal protein L 11
ribsomal protein S23 40s
elongation factor 1-alpha
~ 1 4
actin gamma cytoskeleton

histone H2A
histone H2a.z variant isoform 2
histone H2B family member A
histone 3.3B
histone H4
protein similar to helix destabilizing protein
human ATP synthase alpha chain mitochondria1 precursor

Cytoplasmic fraction
ribosomal protein L5
elongation factor 1-alpha1
ribosomal protein S20
alpha tubulin

beta tubulin
actin depolymerizing factor
GAPDH
ribosomal protein L11 cytosolic

Table 1. H1299 cells were transfected with MDM2 and prepared for proteomic analysis
as described in Experimental Designs. The proteins found to interact with MDM2 in
the cytoplasmic and nuclear fractions are shown in the table.

we found a novel association of MDM2 in H1299 cells with the translation elongation
factor efl-a. Efl-a is involved in catalyzing binding of aminoacyl tRNAs to the A site of
the ribosome during translation and has also been shown to act with the 26s protease
complex to degrade ubiquitin conjugated proteins, thus providing a possible link between
protein synthesis and degradation. Since expression of e f l - a decreases toward the end of
the life span of mouse and human cells but forced expression of this protein has been
shown to prolong the lifespan of drosophila and may function to make cells competent
for growth, we wanted to validate its interaction with MDM2 because of its possible
implications for MDM2 in regulation of cell growth or other yet-unknown functions.

MDM2 interacts with efl-a. To confirm MDM2's interaction with efl-a, H1299
cells were transfected with either vector or MDM2 and the cell lysates were
immunoprecipitated (IP) using an antibody against efl-a or IgG as a control. Western
blotting of the proteins bound to the beads showed that the e f l - a antibody pulled down
efl-a specifically in comparison to IgG, and MDM2 was detected in the MDM2
transfected sample and not in the vector or IgG controls (Figure 28). This suggests that
MDM2 and efl-a specifically interact in H1299 cells, and confirms this interaction from
our proteomic analysis.

Pcrnv
Mdm2

+

-

+

+
-

Figure 28. Validation of the MDM2-efl-a interaction by Western blot. H1299
cells were transfected with MDM2 and immunoprecipitated using an anti-efl-a
antibody (Upstate). MDM2 transfected cells immunoprecipitated using IgG were used
as a control. Detection of MDM2 and e f l - a in the Western blot are shown with
arrows.

EM-a levels are elevated in cancer cells. It had previously been demonstrated that
e f l - a levels are elevated in tumor-derived cells. We therefore compared the endogenous
level of e f l - a in normal W138 cells and the tumor-derived cell lines H1299, MCF7 and
OSACL. Cell extract was made, and equal amounts of the lysate was analyzed by
Western blotting. The results in Figure 29 show that e f l - a levels are elevated in the
tumor-derived cell lines approximately 2-fold in comparison to normal W138 cells,
correlating with the previously reported data.

Actin
Figure 29. EM-a levels are elevated in tumor-derived cells. Extracts were
made from normal W138 and tumor-derived H1299, MCF7 and OSACL cells and were
separated by SDS-PAGE. Efl-a and actin expression is shown by arrows.

MDM2 overexpression does not alter the level of e f l - a expression. We next
wanted to determine whether MDM2 overexpression could affect cellular ef 1-a levels,
and whether this function would be altered in normal versus tumor-derived cells. To
address this issue, we transfected normal W138 and tumor-derived H1299 cells with

vector or MDM2 and analyzed the lysates by Western blotting. The results in Figure 30
show that transfection with MDM2 did not appreciably alter the level of e f l - a in W138 or
H1299 cells, suggesting that the function of the interaction is at a level other than
regulation of expression.

Figure 30. MDM2 does not affect levels of efl-a protein. W138 and H1299 cells
were tranfected with either vector pcmv or pcmv MDM2. Forty-eight hours after
transfection the cells were harvested and lysed, and the extracts separated by SDS-

PAGE. Expression of MDM2, efl-a and actin are shown by arrows.

MDM2 and e f l - a colocalize in the cytoplasm of WI38 cells. Efl-a has been
shown to be mainly localized in the cytoplasm but has also been detected at lower levels
in the nucleus. Since MDM2 is mainly a nuclear protein but can also be shuttled into the
cytoplasm, we wanted to determine where MDM2 and efl-a co-localize in the cell. To

coupled antibody (Santa Cruz, N20), efl-a was stained with an antibody purchased
from Upstate, followed by staining with a rhodamine goat anti-mouse secondary
antibody from Jackson Immunoresearch. Nuclei were stained with DAPI.
Colocalization of MDM2 and efl-a is visualized as a yellow color.

Two domains of MDM2 are required for interaction with efl-a. To determine .the
domains of MDM2 that the protein utilizes to contact efl-a, we employed a series of
MDM2 deletion mutants by immunoprecipitation to find the required interaction
domains. To show expression of MDM2 deletion mutants and efl-a, we chose to see the
interaction from radiolabeled proteins and autoradiography rather than Western blotting
in which detection of the interacting proteins would be complicated by presence of IgG
bands. For this purpose, W138 cells were transfected with MDM2 or its deletion mutants.
Eighteen to twenty-four hours after transfection the cells were labeled with 3

5 ~

methionine, and the extract from these cells was precleared followed by
immunoprecipitation with an anti-MDM2 antibody and the gel exposed to film. The
results in Figure 32 demonstrate that while full-length MDM2 interacts with efl-a
(shown by an arrow), a deletion mutant MDM2 del491-221 loses its ability to interact,
suggesting that a domain located between amino acids 221-491 is required for the
interaction. Following this determination, we tested the ability of MDM2 del491-325 to
associate with efl-a. Figure 33 shows that similar to the full-length protein, this deletion
mutant of MDM2 is capable of interaction. This further defines the e f l - a interaction
domain to within amino acids 221-325 of MDM2.

pCMVMDM2del491-221 pCMV MDM2
pCMV
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-
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Figure 32. MDM2 del491-221 does not interact with efl-a. W138 cells were
transfected with vector pcmv, pcmv MDM2 or pcmv MDM2 de1491-221. Sixteen to
24 hours later the cells were translabeled with 3

5 methionine,
~

harvested and equal

counts were irnmunoprecipitated using an anti-MDM2 antibody-agarose conjugate
(Santa Cruz, SMP14). Proteins that bound to the beads were washed and subjected to
polyacrylamide gel electrophoresis, and the dried gel was exposed to film, as described
in Experimental Designs. The e f l - a band (identified using extract IPed with an antie f l - a antibody) is designated by an arrow. Expression of MDM2 or its deletion mutant
is shown as the darkest band in their respective lanes.

pCMV

Figure 33. MDM2 del491-325 interacts with efl-a. Vector pcmv, pcmv MDM2
or pcmv MDM2 del491-325 were transfected and identified as described in Figure 33
and Experimental Designs. The efl-a band (identified using extract IPed with an antiefl-a antibody) is designated by an arrow. Expression of MDM2 or its deletion mutant
is shown as the darkest band in their respective lanes.

We next tested an N-terminal deletion mutant MDM2 del 1-58 for its ability to form
the interaction. The results in Figure 34 show that loss of the N-terminal58 amino acids
causes MDM2 to lose its ability to associate with efl-a. These data suggest that MDM2
requires two domains for interaction with efl-a, one which is located between amino
acids 1-58 and another located between 221-325. Loss of either of these domains is
enough to prevent MDM2's association with efl-a.

pCMV MDM2 dell-58
pCMV MDM2
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Figure 34. MDM2 dell-58 does not interact with efl-a. Vector pcmv, pcmv
MDM2 or pcmv MDM2 del 1-58 were transfected and identified as described in Figure
33 and Experimental Designs. The e f l - a band (identified using extract IPed with an
anti-efl-a antibody) is designated by an arrow. Expression of MDM2 or its deletion
mutant is shown as the darkest band in their respective lanes.

c. Chapter Summary
To determine novel interactions of the human oncoprotein MDM2, we performed
proteomic analysis of H1299 cells transfected with MDM2. The results of this analysis
confirmed some previously reported interactions and showed a novel interaction of
MDM2 with the translation elongation factor efl-a. To validate this interaction, MDM2
co-IPed with e f l - a in HI299 cells, as presence of these two proteins was specifically
detected in the MDM2-transfected sample by Western blot. Although e f l - a levels were
shown to be higher in tumor-derived cells such as H1299 in comparison to normal W138
cells, MDM2 overexpression was shown to have no effect on expression level of e f l - a in
either cell type. MDM2 and efl-a were found to co-localize in the cytoplasm of W138
cells, supporting the finding that these two proteins interact. Finally, for interaction of
MDM2 with efl-a, MDM2 was determined to require two domains, one of which is
located between amino acids 221-325 and another within the first 58 amino acids of
MDM2.

M. Discussion.
Previous data from our laboratory suggested that in spite of its oncogenic potential,
MDM2 has the ability to induce growth arrest in immortal NIH3T3 cells at the GO-GlIS
phase transition (68). These cells respond to the growth inhibitory property of MDM2
through two domains, ID1 and ID2, located on the MDM2 protein within amino acids
155-220 and 270-324, respectively. A tumorigenic domain found to be located within
amino acids 1-130 of MDM2 induced tumors in nude mice when injected as stable
transfectants of NIH3T3 cells. This led to the hypothesis that the normal function of
MDM2 is to induce growth arrest on overexpression, and inactivation of the growth
inhibitory domains would turn the overexpressed MDM2 into an active growthpromoting protein through the function of its tumorigenic domain. The work in this
dissertation was centered around deciphering the mechanisms of MDM2-mediated cell
cycle arrest. Data published previously by our laboratory suggested that MDM2 arrests
cells at the GO-GlIS phase transition as determined in DNA histograms by flow
cytometry, but this method does not provide a clear distinction between arrest in GO, GI,
or early S, since cells in these phases should stain with similar DNA content. Therefore,
to make this determination we looked for induction of Gl-S cell cycle events in MDM2
arrested cells as a marker to determine the inhibited step, and compared levels of these
proteins in the MDM2 overexpressing cells with untransfected cells in the same
population as controls for normal endogenous levels. Flow cytometry was used in these
experiments instead of Western, as a method to compare levels of endogenous proteins in
individual cells in the sorted transfected and untransfected populations. Normal W138
lung fibroblast, immortal mouse fibroblast NIH3T3 and lung carcinoma H1299 cells were

used to see the effects of MDM2 in cells with varying degrees of genetic damage. Our
analyses show that MDM2 does not significantly alter the level of endogenous cyclin D,
cyclin DICDK specific phosphorylation of Rb or cyclin E in all three cell lines,
suggesting that MDM2 does not prevent cells from crossing the restriction point.
However, MDM2 was shown to down-regulate cyclin A specifically in W138 cells. The
domain of MDM2 involved in this down-regulation was shown to be located within the
N-terminal59-109 amino acids. Since NIH3T3 cells only respond to arrest by ID1 and
ID2 and stable transfectants expressing the N-terminal 1-130 amino acids can be
developed in NIH3T3 cells, this suggests that the cyclin A downregulatory function of
MDM2 represents a third inhibitory domain whose function is inactivated by the cellular
defects present in NIH3T3. Consistent with this, our analyses show that in response to
MDM2 overexpression, NIH3T3 and H1299 cells show no significant decrease in cyclin
A levels. Since previous data from our laboratory demonstrated that loss of MDM2's N-

terminal 58 amino acids eliminates its ability to bind p53, the location of the cyclin A
inhibitory domain between amino acids 59-109 suggests that the MDM2-p53 interaction
is not required for MDM2 to down-regulate cyclin A. Cyclin A is required for
progression into S phase, and in agreement with the ability of MDM2 to down-regulate
cyclin A in normal but not tumor-derived cells, MDM2 del491-110 induced GI arrest in
W138 but not H1299. The GI arrest function was linked to cyclin A down-regulation by
the release of GI arrest after cotransfection of W138 cells with MDM2 and cyclin A
expression plasmids.
The ability of MDM2 to down-regulate cyclin A in W138 but not NIH3T3 or H1299
cells suggests that there is a common genetic defect in these cells that prevents MDM2's

normal function. One common alteration in cancer cells is loss of expression of the
cyclin-dependent kinase inhibitor p16. In NIH3T3 cells the p16 gene is deleted, while in
H1299 cells it is methylated, thus preventing its expression. p16 is a component of the Rb
pathway, and provides an important regulatory control on the GI-S phase transition
leading to expression of cyclin A (Figure 2). We therefore wanted to determine whether
MDM2 requires expression of p16 to down-regulate cyclin A. Silencing of p16 in W138
cells was shown to abrogate the ability of MDM2 to down-regulate cyclin A, visualized
by confocal microscopy, suggesting it is required for this function of MDM2. Reexpression of p16 in H1299 cells either by treatment of cells with 5-aza-deoxycytidine or
cotransfection with a p16 expression plasmid enabled partial restoration of MDM2's
ability to decrease the percent of cyclin A expressing cells or inhibit expression from the
cyclin A promoter, respectively. This suggests the possibility that by restoring function
of p16 in cancer cells that overexpress MDM2, this could turn potentially oncogenic
MDM2 into a growth suppressor. Another component of the Rb pathway is Brgl, which
assembles in complex with Rb at the cyclin A promoter to repress its expression. Using
Brgl siRNA, confocal imaging shows that although MDM2 can down-regulate cyclin A
in W138 cells when cotransfected with scrambled siRNA, silencing of Brgl disables this
process. Thus, another component of the Rb pathway, Brgl, is required for MDM2 to
down-regulate cyclin A.
The finding that MDM2 requires the pl6/Brgl pathway to down-regulate cyclin A
leads to the question of which step in this pathway MDM2 is directly targeting. MDM2
affects the cell cycle at a point after cyclin E induction and before cyclin A is expressed.
The known steps in this process that MDM2 could potentially target are the kinase

activity of cyclin EICDK2 or phosphorylation of Rb or Brgl by this cyclin/kinase
complex. Experiments done to irnmunoprecipitate cyclin E-associated kinase and
analyze its ability to phosphorylate histone H1 suggests that MDM2 does not
significantly affect this kinase activity (data not shown). However, the percent of MDM2
transfection in these assays was not determined, and since the transfection efficiency may
be low, an inhibition of cyclin Ekinase activity by MDM2 may be obscured by a high
percent of contaminating kinase activity from the untransfected cells. Additional
experiments need to be done to test this hypothesis. An alternative to MDM2 functioning
by inhibiting cyclin Ekinase activity is the possibility that MDM2 binds to either Rb or
Brgl, preventing their phosphorylation or preventing Brgl from disassociating from Rb,
thus enabling repression of the cyclin A promoter. However, preliminary data suggests
that H1299 cells do not have detectable levels of Brgl. Since MDM2's ability to regulate
cyclin A expression in H1299 cells can be partially restored by re-expressing p16 in the
absence of detectable Brgl, while silencing of either p16 or Brgl prevents MDM2 from
down-regulating cyclin A in W138 cells, this suggests the possibility that MDM2 does not
directly target either of these proteins but instead requires their contribution toward
providing the normal cellular framework that prevents deregulation of MDM2's growth
regulating function. This is supported by MDM2's differential ability to down-regulate
cyclin A in normal W138 cells, while the unmutated protein loses this function in
NIH3T3 and H1299 cells which harbor genetic/cellular defects.
The data presented in Chapter 4 shows that an MDM2 deletion mutant, MDM2 del
491-1 10 possesses the ability the inhibit BrdU incorporation in W138 but not NIH3T3 or
H1299 cells. Since this deletion mutant contains the cyclin A inhibitory domain which is

functional only in the normal cells, the Brdu data supports the function of this domain as
down-regulating cyclin A, since cyclin A expression initiates progression into S phase
and subsequent DNA replication. A deletion mutant harboring the N-terminal 1- 154
amino acids of MDM2 did not significantly alter the dynamics of BrdU incorporation
from the effects seen by MDM2 del491-110 in the three cell lines, suggesting that this
extended domain of MDM2 may not possess DNA replication inhibitory ability.
Extending the N-terminal portion of MDM2 to include ID1 by transfecting with MDM2
del491-221 also does not have a significant effect on preventing BrdU incorporation in
NIH3T3 and H1299 as it does in W138 cells. Although ID1 present in this deletion
mutant arrests NIH3T3 cells at GO-GUS, though inefficiently, but does not significantly
prevent BrdU incorporation in these cells, this suggests that ID1 present in this deletion
mutant may function downstream of initiation of DNA replication. Prior data from the
laboratory suggested that deletion of the N-terminal58 amino acids from MDM2 del
491-221 leads to more efficient growth arrest, suggesting that amino acids 1-58 may
provide a signal that cooperates with the function of ID1. This signal is located within
the defined tumorigenic domain of MDM2, and if ID1 functions after replication
initiation it may play a role in this process. Finally, transfection with full-length MDM2
was found to efficiently inhibit BrdU incorporation in all three cell lines. Since further
inclusion of ID2 prevents BrdU incorporation by the full-length protein in H1299 and
NIH3T3 where ID1 and the cyclin A inhibitory domain do not, this suggests that ID2
prevents replication initiation. Thus, MDM2 possesses three inhibitory domains, each
functioning potentially at a different step in the cell division cycle.

In determining the significance of these domains for the cell, a model can be proposed
in which MDM2 is induced in response to oncogenic challenges in normal cells and
provides protection against genetic damages by inihibiting cell cycle progession through
three different mechanisms. Two scenarios can be envisioned. In one, the three
inhibitory domains of MDM2 provide a way to arrest cells that have already committed
to replicate and are at different stages of progression after passing the restriction point so
that once genetic damage is sustained MDM2 has flexibility to inhibit cell growth
independent of the cell cycle step in which the damage was conferred. In another
scenario, MDM2 may possess the three inhibitory domains so that it provides multiple
levels of protection for arresting growth of cells even when cellular defects exist that
inactivate its function in the other growth inhibitory pathways. The hypothesis that
multiple genetic damages increasingly desensitize cells to the growth arrest function of
MDM2 is suggested by the data in Chapter 5 showing that tumor-derived cells which
harbor more genetic damages require more MDM2 to achieve a growth arrest similar to
that achieved with the less damaged NIH3T3 and, in turn, MDM2 can arrest normal
W138 cells with similar efficiency at even lower levels. The hypothesis that MDM2 may
provide multiple levels of protection is reflected in the multiple mechanisms eukaryotic
cells use to prevent rereplication of DNA during the normal cell division cycle. For
example, eukaryotic cells employ cyclin-dependent kinases to phosphorylate the origin
recognition complex, downregulate cdc6 activity and exclude the MCM2-7 complex
from the nucleus to prevent re-initiation of DNA replication (74). Evidence presented in
this dissertation suggests that defects present in the cellular pathways that MDM2 utilizes
to induce growth arrest may inactivate its function. Ultimately, these damages may not

only eliminate MDM2's growth suppressive functions but enable MDM2's oncogenic
function through the action of its tumorigenic domain.
To find novel protein interactions of MDM2 that may further elucidate MDM2's role
in cellular processes, we performed proteomic analysis of MDM2 overexpression in
H1299 cells. This endeavor identified interaction of MDM2 with elongation factor 1alpha (efl-a). The interaction was confirmed by immunoprecipitation and Western
blotting. MDM2 was found to not significantly alter the expression of e f l - a in either
normal W138 or tumor-derived H1299 cells, suggesting that the function or dysfunction
of the interaction is not to change level of protein expression. Confocal localization
studies demonstrated that MDM2 and e f l - a colocalize in the cytoplasm, suggesting this
is the place for the function of their association. Deletion mutant analysis suggested that
two domains of MDM2 are required for interaction with efl-a, one located between
amino acids 1-58 and another between amino acids 221-325. The data presented in
Chapter 5 identify and validate that MDM2 and e f l - a interact but leave the question
open as to the functional significance of the interaction. E f l - a is involved in catalyzing
transfer of aminoacyl tRNAs to the A site during translation, but our prelimary data
suggests that MDM2 overexpression in H1299 cells does not affect translation. This is
also evidenced in the fact that our deletion mutant studies to determine the interaction
domain, which relied on translabeling with "S methionine, led to visualization of labeled
protein bands in the gel. MDM2 requires two domains to interact with efl-a, one
overlapping with the p53 interaction domain and another with a domain that harbors the
acidic domain, ID2, and the pl4ARF, spl and Rb binding sites. Since elimination of the
N-terminal58 amino acids of MDM2 prevents MDM2's interaction with p53 as well as

interaction with efl-a, this may provide some clue to the function. It is also interesting
that the other domain required for interaction involves pl4ARF, and association of
pl4ARF with MDM2 has been shown to stabilize p53. Whether the MDM2-efl-a
interaction has any role in this process will have to be tested with further experiments.

N. Experimental Designs.
General Methods.
Plasmids and MDM2 deletion mutants. The MDM2 cDNA was a generous gift
from Bert Vogelstein (23). Construction of plasmids expressing the full-length MDM2
and its deletion mutants has been described earlier in detail (9, 12). The plasmid
pCMVpl6 was constructed from a pbluescript p16 plasmid, which was a generous gift
from Martine Roussel.

Cells. NIH3T3, WI38, H1299 cells were purchased from American Type Culture
Collection and were maintained in media suggested by the supplier. NIH3T3 cells were
maintained in DMEM with 10% calf serum. W138 cells were maintained in Minimum
Essential Media Eagle with 10% fetal bovine serum. H1299 cells were maintained in
RPMI with 10% fetal bovine serum.

Immunofluorescent staining and confocal imaging. Irnmunofluorescent staining
and confocal imaging were performed following a method reported by Lohrum et a1 (25).
Briefly, normal diploid W138 cells were seeded on sterile coverslips in a 6-well culture
dish, and were transfected with 2 pg MDM2 expression plasmid per coverslip. The cells
were fixed 48 hours after transfection using 4% paraformaldehyde for 10 minutes at room
temperature with constant shaking. The cells were then washed three times in phosphate
buffered saline (PBS), permeabilized in ice cold PBS containing 0.2% triton X-100 for 5
minutes and blocked in PBS containing 0.5% bovine serum albumin at room temperature
for 30 minutes. For MDM21cyclin A staining, the fixed cells were consecutively
imrnunostained overnight at 4°C with a FITC-coupled anti-MDM2 antibody (N20, Santa
Cruz) and a rhodamine-coupled anti-cyclin A antibody (SC75 1 TritC, Santa Cruz) in

blocking solution. The antibody used to detect Brgl was purchased from Santa Cruz (SC17796) followed by staining with a rhodamine goat anti-mouse secondary antibody from
Jackson Imrnunoresearch (1 15-295-146). For detection of MDM2lefl-a, cells were
stained with a FITC-coupled anti-MDM2 antibody (N20, Santa Cruz) followed by
staining with an anti-efl-a primary antibody (Upstate, 05-235). The secondary antibody
used against the primary efl-a antibody was a rhodamine goat anti-mouse secondary
antibody from Jackson Immunoresearch (1 15-295-146). The slides were then washed
three times in PBS and once in water, air dried and mounted with Prolong Gold Antifade
with DAPI (Molecular Probes). The coverslips were then analyzed under a confocal
microscope (Zeiss) under 63X magnification.

Western blot analysis. Western blot analysis was carried out essentially as
previously described (12, 17). Briefly, cells were washed three times in PBS and scraped
from the plate in PBS and transferred to a microfuge tube. Cells were then spun at 900 rcf
for 10 minutes. The supernatant was removed and cells were lysed in a volume of
laemmli loading buffer equivalent to the size of the cell pellet and were boiled 5 minutes.
Cells were separated in a 10% polyacrylamide gel and transferred to 0.45 pm
nitrocellose. For detecting cyclin A in the blot, cyclin A antibody was purchased from
Santa Cruz (SC-75 1). p-actin antibody was purchased from Sigma (A-5441). efl-a was
detected using an antibody from Upstate (05-235). The blots were developed using ECL
purchased from Amersham.

Chapter 3 Methods.
Transfections for flow cytometry. Cells were seeded 18 to 24 hours before
transfection at 0.4-1 X lo5 cells per 10 cm dish and transfected by the calcium phosphate

method (9, 12, 17). The cells were transfected with plasmids (10 pg) that express wild
type or deletion mutants of MDM2. Thirty to forty-eight hours after transfection the cells
were collected and fixed. In the MDM2Icyclin A cotransfection experiment, W138 cells
were transfected with 10 pg of a plasmid expressing cyclin A along with 10 pg of a
plasmid expressing MDM2 del49 1- 110.

Antibodies. The human cyclin D antibody was reactive for cyclin D l , D2 and D3
and was used to stain W138 and H1299 cells. For cell cycle analysis in MDM2 Del491110 overexpressing cells a primary antibody to recognize the N-terminal epitope (N20,
Santa Cruz) and a FITC conjugated secondary anti-rabbit IgG (Oncogene Science) were
used. FITC conjugated N20 (to detect C-terminal deletion mutant MDM2 Del491-110)
and FITC conjugated SMP14 (to detect the N-terminal deletion mutants of MDM2) was
purchased from Santa Cruz. For other flow cytometric experiments N20 was coupled
with phycoerythrin (PE) using a phycoerythrin conjugation kit (Phycolink) from
Prozyme. The PE-coupled antibody was separated from unconjugated PE and antibody
using a Bio-Gel A-0.5m column. D-type cyclins were detected using FITC conjugated
anti cyclin D antibody set from Pharmingen. The human cyclin D antibody was reactive
for cyclin Dl, D2 and D3. The FITC conjugated anti- cyclin E and A antibodies and anti
Rb antibody for cyclin D- specific phosphorylation site (Ser 795) was purchased from
Santa Cruz.

Flow cytometry. Cell cycle Analysis: Methods for cell cycle analysis have been
described earlier (17, 18, 24). Cells were harvested 30 to 48 hours after transfection and
fixed with 70% ethanol for overnight at 4°C. The fixed cells were incubated with
appropriate antibody for 2 hours and an FITC-coupled secondary antibody for one hour

in PBS, 0.5% BSA and 0.5% Tween 20. Cells were then washed three times in PBS and
0.5% BSA. To stain DNA with propidium iodide (PI), the cells were incubated with
0. lmg per ml RNase A, 50 pg per ml propidium iodide, 0.1% NP40 in a trisodium citrate
buffer for 30 minutes. The samples were analyzed in a fluorescence activated cell sorter
(Elite, Coulter or FAC

tar^'"" Becton Dickinson) in a flow cytometry core facility.

Relative levels of MDM2 expression per cell were determined by FITC-fluorescence
intensity in the green channel (525 nm). Mock-transfected cells were used to determine
the background fluorescence. Vector-transfected cells or cells transfected with a plasrnid
expressing an irrelevant protein did not induce growth arrest (17). Cells showing higher
FITC-fluorescence intensity than mock-transfected cells were gated. The intensity of PI
staining was recorded in the red channel.

Comparison of cyclin expression. To estimate and compare levels of cyclins or
cyclin D-specific Rb phosphorylation, cells were incubated with FITC-coupled
appropriate antibody or the respective matched IgG isotype after incubation with PEcoupled anti-MDM2 antibody. Intensities of the fluorescent dyes were plotted against
cell number and compared as shown in the Figures. A minimum of 8,000 MDM2
overexpressing (transfected) cells was analyzed in each experiment. Experiments were
repeated several times.

Transfection with p16- or Brgl-siRNA. For confocal experiments with siRNA, 5
pg of MDM2 expression plasmid was transfected with 80 pmol either p16- or BrglsiRNA using a nucleofector from amaxa. W138 cells were harvested and nucleofected
using 3 X lo6cells per transfection and nucleofector Program U-23. After nucleofection,
cells were plated on sterile coverslips and fixed 48 hours later.

Transient transfection promoter analysis. Transient transfection promoter analysis
was performed by a method published by Deb et a1 (26). To determine cyclin A
promoter activity, H1299 cells were transfected using Fugene 6 (Roche) with a luciferase
reporter plasmid under the control of luciferase promoter (26) in the presence or absence
of MDM2 or p16. For this experiment the amount of DNA used was 500 ng of vector,
100 ng of p16 expression plasmid, and 400 ng of MDM2 expression plasmid. Cell
extracts containing equal amount of protein were assayed for luciferase activity.
Luciferase assays were carried out using a commercial kit from Promega. Experiments
were repeated several times.

5'-deoxy-azacytidine treatment: H1299 cells were treated for 72 hours with 5-aza2'-deoxycytidine before transfection with MDM2 Del491-110 expression plasmid, and
the treatment was continued for another 48 hours after which the cells were harvested and
fixed.

Chapter 4 Methods.
Analysis of Bromodeoxyuridine incorporation: Bromodeoxyuridine incorporation
studies were performed by a method reported earlier (18,24). Cells transfected using the
calcium phosphate method with hMDM2 expression plasmids or mock-transfected cells
were incubated with bromodeoxyuridine (BrdU, 10 pM) for 30 to 40 minutes 48 hours
after transfection. Cells were then harvested by trypsinization, washed and fixed as
described. Fixed cells were rehydrated and treated consecutively with HCl(2N) and
sodium borate (O.1M) to partially denature DNA since the antibody can recognize BrdU
in single-stranded DNA. A PE-coupled hMDM2 antibody and an FITC coupled antiBrdU antibody were used to detect hMDM2 and BrdU respectively. The MDM2-PE

antibody was described previously in Chapter 3 methods. BrdU was detected using a
FITC-coupled anti-BrdU monoclonal antibody set from Pharmingen. Cells were then
incubated with 7AAD (20 pg per ml) to stain DNA and analyzed in a flow cytometry
core facility.

Flow cytometry. Different concentrations of MDM2 expression plasmids were
transfected by nucleofection into WI38, NIH3T3 and H1299 cells. Forty-eight hours
after transfection the cells were harvested and fixed and stained for flow cytometric
analysis as described previously using a primary antibody 2AlO (provided by Arnold
Levine) and an anti-mouse IgG (goat) fluorescein conjugated secondary antibody
(Calbiochem DC13L). DNA was stained using propidium iodide.

Chapter 5 Methods.
Coimmunoprecipitationof MDM2-interacting proteins. To identify MDM2interacting proteins, cells were transfected with an MDM2 expression plasmid using the
calcium phosphate method (9, 12, 17). Forty-eight hours after transfection, cells were
washed in DPBS twice and the pellet was suspended in 990 p1 Buffer A (10 mM Hepes,
10 mM KC1, 1.5 rnM MgC12, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 0.1 mM PMSF,
and 1X protease inhibitors Calbiochem Cocktail Set I11 (539134)). To this, 10 p1 of 10%
TritonX-100 was added and the suspension was incubated 5 minutes on ice. Cells were
spun at 1700g at 4°C for 4 minutes. The supernatant was collected and spun at 20,000g
at 4°C for 15 minutes for clarification, and the supernatant was taken as the cytoplasmic
extract. The pellet generated from the Buffer A treatment (nuclei) was suspended in 190
p1 Buffer A and 1mM CaC12. For every two plates harvested, 1 unit of micrococcal
nuclease was added. The pellet was vortexed and incubated at 37" for 15 minutes. To

stop the reaction, 0 . 4 ~ of
1 250 mM EGTA was added for every two plates harvested.
Cells were spun at 1700g at 4' for 4 minutes. To lyse the nuclei pellet, 1 ml of 10s
buffer was added (50 mM Hepes, 0.1M NaC1,0.3% NP40,O.lM Triton-X-100, 10 mM
NaP04 pH 7.0, 1 mM NaF, 0.14 mM PMSF, 0.5 mM DTT and 1X protease inhibitors
Calbiochem Cocktail Set I11 (539134)). Lysate was passed through a 2lguage needle,
lysed on ice 5 minutes and spun at 1700g at 4' for 4 minutes. The supernatant was kept
as the nuclear extract. Cytoplasmic and nuclear extracts were separately precleared in
lml of their corresponding buffers using 12 pl normal mouse IgG agarose (Santa Cruz
SC-2343) for 1.5 hours at 4' with tilting. The beads were pelleted at 800g for 2 minutes
and MDM2 was immunoprecipitated with a monoclonal antibody coupled directly with
agarose beads (Santa Cruz, SMP14 SC-965). The immunoprecipitate was washed two
times to remove contaminating unbound proteins using 10s buffer, followed by two
washes with 10 mM phosphate pH 6.8. For elution 40 pl of 100 mM glycine pH 2.5 was
added to the beads and incubated 10 minutes at room temperature. The tubes were spun
at 100 g for 2 minutes at room temperature and the supernatant was added to 4 1 1 of 0.5M
phosphate pH 8.0. The elution step was then repeated one additional time. The fractions
were then desalted using a Microcon filter device (42420) following the manufacturer's
protocol. Ammonium bicarbonate was then added to a final concentration of O.1M and
the associated proteins were then digested with trypsin and analyzed by the Peak Parking
protocol described below. Proteins that bind nonspecifically to either the antibody or IgG
coupled agarose act as false positives but can usually be identified as such by passing the
sample through agarose beads coupled to irrelevant antibody. Only proteins that bind

nonspecifically to the antibody-coupled beads are detected in this experiment and can be
subtracted from those found in the first experiment.

Mass spectrometric analysis. Mixtures were analyzed directly in Dr. Hunt's laboratory
by employing "Peak Parking Technology" developed and patented at the University of
Virginia (69-70). Immunoprecipitated and eluted samples were digested with trypsin
and the resulting mixture of tryptic peptides (30 peptideslprotein) were then analyzed by
nanoflow-HPLC (5-200 nLlmin) interfaced directly to electrospray ionization on a
ThermoFinnigan, LC-Deca instrument. Peak Parking Technology under control of the
mass spectrometer data system is employed to extend the sample peak width from 10 sec
to 200 sec and thus to give the instrument time to record MSMS spectra on more than a
hundred different peptides that happen to elute in the same 10 sec chromatographic time
window. Samples were fractionated initially at a flow rate of 200 nLlmin on the
microcapillary HPLC column and the mass spectrometer was scanned repetitively from
d z 300-2,000. When sample elutes from the column and the ion current detected by the
instrument increases above background, the data system reduces flow rate to 4 0 nL1min
and the instrument repetitively cycles through a program of six scans. (Software for this
program was developed for Dr. Hunt's laboratory by ThermoFinnigan and is now
commercially available.) The first spectrum (2 sec) records the masses of (M+H)+ and
(M+2H)++ ions observed for the components eluting under the chromatographic peak.
The next five scans (10 sec) record MSMS spectra to generate sequence information on
the five most abundant species observed in spectrum #l. These masses are then placed
on an exclusion list along with the corresponding isotope peaks.

The next scan is used to re-measure ions characteristic of the component molecular
weights and the next five scans record MSMS spectra on the five most abundant species
not already on the exclusion list. MSMS spectra can be recorded on as many as 100
different co-eluting peptides using this protocol. Once the list of candidates to be
fragmented is exhausted, the flow rate is changed back to 200 nllmin until the next group
of peptides is detected. The above process is then repeated. At the end of the
chromatographic run, proteins in the original mixture are identified by processing the
complete set of MSMS spectra against the protein and nucleic acid databases using the
SEQUEST software program (71). Up to 6,000 sequences on tryptic peptides can be
obtained in a single 4 hr chromatographic run with the above technology. Peptides
present at the 5-10 fmol level in complex mixtures were readily identified with this
approach.

Translabeling and immunoprecipation. Cells were transfected with MDM2
expression plasmids using the nucleofection method. H1299 cells were nucleofected
using program T-20 while program U-23 was used for W138 cells. In both cases, 3 x106
cells were used per transfection. Sixteen to 24 hours after transfection, cells were starved
in methionine-free DMEM for one hour and incubated for two hours in 1.4 ml
methionine-free DMEM with 10% dialyzed FBS and 16 pl 3

5 methionine.
~

Plates were

washed three times with PBS and lysed in 10s buffer on ice for 10 minutes. Cells were
scraped from the plate and passed through a 21 guage needle and spun at 3220 g for 6
minutes at 4°C. The extracts were precleared for 1.5 hours using normal mouse IgG
agarose (Santa Cruz SC-2343). Equal counts of each supernatant were
irnmunoprecipitated with an agarose-conjugated anti-MDM2 antibody (Santa Cruz,

SMP14 SC-965) overnight at 4' with constant tilting. Beads were then washed three
times with 10s buffer, one time with 0.8M LiCl followed immediately by one wash with
TE buffer pH 8.0. After each wash cells were spun at 800 g. The beads were then boiled
in larnmeli loading buffer and subjected to gel electrophoresis. The gel was incubated for
1 hour in Enhance (Perkin Elmer 6NE9701) followed by incubation in deionized water
for exactly 25 minutes and then a 10 minute incubation in 10% acetic acid/2%glycerol.
The gel was then dried for two hours and exposed to film.
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